Novo Nordisk: Semaglutide Heralds Commercial Dawn Of Obesity Market

 
• By Sten Stovall

The Danish group expects its experimental GLP-1 semaglutide to prove so effective and safe in fighting obesity that it will spur commercial viability for medical treatment of the condition.

Overweight
Semaglutide Will Lead Commercial Dawning Of Global Obesity Market, Novo Nordisk Believes • Source: Shutterstock

More from Strategy

More from Business